6190.TSE · PhoenixBio Co., Ltd

-

Please sign in to comment on 6190.TSE

1 Comment

Admin

4 years, 8 months ago

PhoenixBio Co., Ltd is currently in a long term uptrend where the price is trading 2.7% above its 200 day moving average.

From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.1.

PhoenixBio Co., Ltd's total revenue sank by 35.9% to $200M since the same quarter in the previous year.

Its net income has dropped by 185.1% to $-80M since the same quarter in the previous year.

Based on the above factors, PhoenixBio Co., Ltd gets an overall score of 2/5.

Sector	Healthcare
Industry	Biotechnology
ISIN	JP3803010002
Exchange	TSE
CurrencyCode	JPY

Beta	0.12
Market Cap	2B
PE Ratio	None
Target Price	None
Dividend Yield	None

ABOUT

PhoenixBio Co., Ltd

PhoenixBio Co., Ltd. provides contract testing services for medical product development in Japan, the United States, and internationally. The company offers PXB-mouse, a chimeric mouse with a humanized liver used in drug development experiments; and PXB-cells, human hepatocytes for in vitro studies and experiments, as well as HBV study services. Its products are used in gene therapeutics, MASH/MAFLD, viral hepatitis, DMPK/toxicity, and custom transplantations applications. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.

6190.TSE · PhoenixBio Co., Ltd

-

PhoenixBio Co., Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest PhoenixBio Co., Ltd using a moving average strategy